Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success
October 21 2019 - 1:44AM
Dow Jones News
By Carlo Martuscelli
Roche Holding AG (RO.EB) said Monday that a phase 3 study
combining cancer drugs Tecentriq and Avastin had met its primary
targets, showing efficacy in patients with hepatocellular
carcinoma.
The two drugs together increased overall as well as
progression-free survival in patients with inoperable
hepatocellular carcinoma who hadn't previously received systemic
therapy, the pharmaceutical company said.
Roche said that a breakdown of the data will be presented at a
coming medical conference.
"We are very pleased with the results of our study testing the
combination of Tecentriq and Avastin, which marks the first
treatment in more than a decade to improve overall survival in
people with unresectable hepatocellular carcinoma who have not
received prior systemic therapy," said Chief Medical Officer Levi
Garraway.
The company said it will submit the data from the study to
health regulators globally, including in the U.S., Europe and
China.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com;
@carlomartu
(END) Dow Jones Newswires
October 21, 2019 01:29 ET (05:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024